These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25089874)

  • 1. Molecular research in urology 2014: update on PET/MR imaging of the prostate.
    Wetter A
    Int J Mol Sci; 2014 Jul; 15(8):13401-5. PubMed ID: 25089874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
    Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
    Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancement of MR and PET/MR in Prostate Cancer.
    Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
    Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
    Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography and molecular imaging of the prostate: an update.
    Lawrentschuk N; Davis ID; Bolton DM; Scott AM
    BJU Int; 2006 May; 97(5):923-31. PubMed ID: 16643472
    [No Abstract]   [Full Text] [Related]  

  • 11. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Choi JY; Yang J; Noworolski SM; Behr S; Chang AJ; Simko JP; Nguyen HG; Carroll PR; Kurhanewicz J; Seo Y
    Radiology; 2017 Feb; 282(2):429-436. PubMed ID: 27513849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.
    Ferraro DA; Rupp NJ; Donati OF; Messerli M; Eberli D; Burger IA
    Clin Nucl Med; 2019 Apr; 44(4):e291-e293. PubMed ID: 30688746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choline-based imaging of prostate cancer with combined [
    Wetter A; Grüneisen J; Fliessbach K; Lütje S; Schaarschmidt B; Umutlu L
    Clin Imaging; 2017; 42():198-202. PubMed ID: 28110202
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
    Osmany S; Zaheer S; Bartel TB; Johnston M; Peh WM; Barmaky S; Jadvar H
    AJR Am J Roentgenol; 2019 Aug; 213(2):286-299. PubMed ID: 31166760
    [No Abstract]   [Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of multimodality multiparametric 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer.
    Takei T; Souvatzoglou M; Beer AJ; Drzezga A; Ziegler S; Rummeny EJ; Schwaiger M; Eiber M
    Clin Nucl Med; 2012 Sep; 37(9):918-9. PubMed ID: 22889793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.